v3.24.3
Product Sales
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Product Sales Product Sales
Net product sales consist of the following:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In millions)2024202320242023
EYLEA HD®
U.S.$392.3 $42.7 $896.5 $42.7 
EYLEA®
U.S.1,144.6 1,448.2 3,576.7 4,382.1 
Total EYLEA HD and EYLEAU.S.1,536.9 1,490.9 4,473.2 4,424.8 
Libtayo®
U.S.194.5 144.1 536.1 384.0 
Libtayo
Rest of world
94.1 88.3 313.8 235.3 
Total Libtayo
Global
288.6 232.4 849.9 619.3 
Praluent®
U.S.52.9 40.4 179.0 121.1 
Evkeeza®
U.S.32.4 19.1 87.6 53.3 
Inmazeb®
Global
35.6 3.3 36.6 7.7 
$1,946.4 $1,786.1 $5,626.3 $5,226.2 
As of September 30, 2024 and December 31, 2023, the Company had $4.142 billion and $3.888 billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.
The Company had product sales to certain customers that each accounted for more than 10% of total gross product revenue for the three and nine months ended September 30, 2024 and 2023. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2024202320242023
Besse Medical, a subsidiary of Cencora, Inc.51 %53 %51 %52 %
McKesson Corporation24 %24 %24 %25 %